Effect of Calcium Channel Blockers on Antiplatelet Activity of Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention: Insights from the PTRG-DES Consortium

Aims: Calcium channel blockers (CCBs) are frequently co-administered with clopidogrel in cardiovascular disease. Although an inhibitory drug interaction exists between them, comprehensive large-scale studies for its validation are lacking. We investigated interactions between CCBs and clopidogrel us...

Full description

Saved in:
Bibliographic Details
Main Authors: HoungBeom Ahn MD, Hyun-Wook Chu MD, Ae-Young Her MD, PhD, Young-Hoon Jeong MD, PhD, Byeong-Keuk Kim MD, PhD, Hyung Joon Joo MD, PhD, Kiyuk Chang MD, PhD, Yongwhi Park MD, PhD, Sung Gyun Ahn MD, PhD, Sang Yeup Lee MD, PhD, Jung Rae Cho MD, PhD, Hyo-Soo Kim MD, PhD, Moo Hyun Kim MD, PhD, Do-Sun Lim MD, PhD, Eun-Seok Shin MD, PhD, Jung-Won Suh MD, PhD
Format: Article
Language:English
Published: SAGE Publishing 2024-11-01
Series:Journal of Cardiovascular Pharmacology and Therapeutics
Online Access:https://doi.org/10.1177/10742484241298150
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1846164233076604928
author HoungBeom Ahn MD
Hyun-Wook Chu MD
Ae-Young Her MD, PhD
Young-Hoon Jeong MD, PhD
Byeong-Keuk Kim MD, PhD
Hyung Joon Joo MD, PhD
Kiyuk Chang MD, PhD
Yongwhi Park MD, PhD
Sung Gyun Ahn MD, PhD
Sang Yeup Lee MD, PhD
Jung Rae Cho MD, PhD
Hyo-Soo Kim MD, PhD
Moo Hyun Kim MD, PhD
Do-Sun Lim MD, PhD
Eun-Seok Shin MD, PhD
Jung-Won Suh MD, PhD
author_facet HoungBeom Ahn MD
Hyun-Wook Chu MD
Ae-Young Her MD, PhD
Young-Hoon Jeong MD, PhD
Byeong-Keuk Kim MD, PhD
Hyung Joon Joo MD, PhD
Kiyuk Chang MD, PhD
Yongwhi Park MD, PhD
Sung Gyun Ahn MD, PhD
Sang Yeup Lee MD, PhD
Jung Rae Cho MD, PhD
Hyo-Soo Kim MD, PhD
Moo Hyun Kim MD, PhD
Do-Sun Lim MD, PhD
Eun-Seok Shin MD, PhD
Jung-Won Suh MD, PhD
author_sort HoungBeom Ahn MD
collection DOAJ
description Aims: Calcium channel blockers (CCBs) are frequently co-administered with clopidogrel in cardiovascular disease. Although an inhibitory drug interaction exists between them, comprehensive large-scale studies for its validation are lacking. We investigated interactions between CCBs and clopidogrel using a large-scale national registry of patients who underwent percutaneous coronary intervention (PCI). Methods and Results: The Platelet function and genoType-Related long-term Prognosis-Platelet Function Test consortium investigates the association between platelet function test and long-term prognosis during dual antiplatelet therapy including clopidogrel in patients using drug-eluting stents. We compared the ex vivo platelet reactivity using the VerifyNow P2Y12 test and clinical outcomes between CCB users and non-users. Between 2003 and 2018, 11 714 patients were enrolled and categorized into two groups according to CCB usage. A composite endpoint encompassing all-cause mortality, myocardial infarction, stent thrombosis, or stroke was defined as a major adverse cardiac and cerebrovascular event (MACCE). During the 5-year follow-up period, no significant differences were observed in P2Y12 reaction units (215.8 ± 84.7 vs 218.4 ± 76.7, P  = .156), MACCEs, major bleeding, or high platelet reactivity rates, even after adjusting for propensity score matching (PSM) and inverse probability of treatment weighting (IPTW). When limited to the high platelet reactivity cohort (≥252 PRU), the results remained consistent for MACCE [PSM-adjusted, HR: 0.923 (0.644-1.323), P -value .663; IPTW-adjusted, HR: 1.300 (0.822-2.056), P -value .262]. Conclusions: CCB and clopidogrel co-administration does not appear to significantly impact clopidogrel responsiveness or clinical outcomes. Despite these promising results, further investigation may be warranted. Clinical trial registration: Platelet Function and genoType-Related Long-term progGosis in DES-treated Patients: A Consortium From Multi-centered Registries [PTRG-DES]; NCT04734028
format Article
id doaj-art-bcadf80ab3ea4b5a853da1218d58d3c2
institution Kabale University
issn 1940-4034
language English
publishDate 2024-11-01
publisher SAGE Publishing
record_format Article
series Journal of Cardiovascular Pharmacology and Therapeutics
spelling doaj-art-bcadf80ab3ea4b5a853da1218d58d3c22024-11-18T12:03:19ZengSAGE PublishingJournal of Cardiovascular Pharmacology and Therapeutics1940-40342024-11-012910.1177/10742484241298150Effect of Calcium Channel Blockers on Antiplatelet Activity of Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention: Insights from the PTRG-DES ConsortiumHoungBeom Ahn MD0Hyun-Wook Chu MD1Ae-Young Her MD, PhD2Young-Hoon Jeong MD, PhD3Byeong-Keuk Kim MD, PhD4Hyung Joon Joo MD, PhD5Kiyuk Chang MD, PhD6Yongwhi Park MD, PhD7Sung Gyun Ahn MD, PhD8Sang Yeup Lee MD, PhD9Jung Rae Cho MD, PhD10Hyo-Soo Kim MD, PhD11Moo Hyun Kim MD, PhD12Do-Sun Lim MD, PhD13Eun-Seok Shin MD, PhD14Jung-Won Suh MD, PhD15 Department of Internal Medicine, , Seoul, South Korea Department of Cardiology, , Hallym University College of Medicine, Seoul, South Korea Division of Cardiology, Department of Internal Medicine, , Chuncheon, South Korea Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, South Korea Severance Cardiovascular Hospital, , Seoul, South Korea Department of Cardiology, Cardiovascular Center, , Korea University College of Medicine, Seoul, South Korea Division of Cardiology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea Division of Cardiology, Department of Medicine, Gyeongsang National University School of Medicine, Changwon, South Korea Department of Cardiology, Yonsei University Wonju Severance Christian Hospital, Wonju, South Korea Division of Cardiology, , Gwangmyeong, South Korea Cardiology Division, Department of Internal Medicine, Kangnam Sacred Heart Hospital, Hallym University College of Medicine, Seoul, South Korea Department of Internal Medicine and Cardiovascular Center, , Seoul, South Korea Department of Cardiology, , Busan, South Korea Department of Cardiology, Cardiovascular Center, , Korea University College of Medicine, Seoul, South Korea Division of Cardiology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, South Korea Department of Internal Medicine, , Seoul, South KoreaAims: Calcium channel blockers (CCBs) are frequently co-administered with clopidogrel in cardiovascular disease. Although an inhibitory drug interaction exists between them, comprehensive large-scale studies for its validation are lacking. We investigated interactions between CCBs and clopidogrel using a large-scale national registry of patients who underwent percutaneous coronary intervention (PCI). Methods and Results: The Platelet function and genoType-Related long-term Prognosis-Platelet Function Test consortium investigates the association between platelet function test and long-term prognosis during dual antiplatelet therapy including clopidogrel in patients using drug-eluting stents. We compared the ex vivo platelet reactivity using the VerifyNow P2Y12 test and clinical outcomes between CCB users and non-users. Between 2003 and 2018, 11 714 patients were enrolled and categorized into two groups according to CCB usage. A composite endpoint encompassing all-cause mortality, myocardial infarction, stent thrombosis, or stroke was defined as a major adverse cardiac and cerebrovascular event (MACCE). During the 5-year follow-up period, no significant differences were observed in P2Y12 reaction units (215.8 ± 84.7 vs 218.4 ± 76.7, P  = .156), MACCEs, major bleeding, or high platelet reactivity rates, even after adjusting for propensity score matching (PSM) and inverse probability of treatment weighting (IPTW). When limited to the high platelet reactivity cohort (≥252 PRU), the results remained consistent for MACCE [PSM-adjusted, HR: 0.923 (0.644-1.323), P -value .663; IPTW-adjusted, HR: 1.300 (0.822-2.056), P -value .262]. Conclusions: CCB and clopidogrel co-administration does not appear to significantly impact clopidogrel responsiveness or clinical outcomes. Despite these promising results, further investigation may be warranted. Clinical trial registration: Platelet Function and genoType-Related Long-term progGosis in DES-treated Patients: A Consortium From Multi-centered Registries [PTRG-DES]; NCT04734028https://doi.org/10.1177/10742484241298150
spellingShingle HoungBeom Ahn MD
Hyun-Wook Chu MD
Ae-Young Her MD, PhD
Young-Hoon Jeong MD, PhD
Byeong-Keuk Kim MD, PhD
Hyung Joon Joo MD, PhD
Kiyuk Chang MD, PhD
Yongwhi Park MD, PhD
Sung Gyun Ahn MD, PhD
Sang Yeup Lee MD, PhD
Jung Rae Cho MD, PhD
Hyo-Soo Kim MD, PhD
Moo Hyun Kim MD, PhD
Do-Sun Lim MD, PhD
Eun-Seok Shin MD, PhD
Jung-Won Suh MD, PhD
Effect of Calcium Channel Blockers on Antiplatelet Activity of Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention: Insights from the PTRG-DES Consortium
Journal of Cardiovascular Pharmacology and Therapeutics
title Effect of Calcium Channel Blockers on Antiplatelet Activity of Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention: Insights from the PTRG-DES Consortium
title_full Effect of Calcium Channel Blockers on Antiplatelet Activity of Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention: Insights from the PTRG-DES Consortium
title_fullStr Effect of Calcium Channel Blockers on Antiplatelet Activity of Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention: Insights from the PTRG-DES Consortium
title_full_unstemmed Effect of Calcium Channel Blockers on Antiplatelet Activity of Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention: Insights from the PTRG-DES Consortium
title_short Effect of Calcium Channel Blockers on Antiplatelet Activity of Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention: Insights from the PTRG-DES Consortium
title_sort effect of calcium channel blockers on antiplatelet activity of clopidogrel in patients undergoing percutaneous coronary intervention insights from the ptrg des consortium
url https://doi.org/10.1177/10742484241298150
work_keys_str_mv AT houngbeomahnmd effectofcalciumchannelblockersonantiplateletactivityofclopidogrelinpatientsundergoingpercutaneouscoronaryinterventioninsightsfromtheptrgdesconsortium
AT hyunwookchumd effectofcalciumchannelblockersonantiplateletactivityofclopidogrelinpatientsundergoingpercutaneouscoronaryinterventioninsightsfromtheptrgdesconsortium
AT aeyounghermdphd effectofcalciumchannelblockersonantiplateletactivityofclopidogrelinpatientsundergoingpercutaneouscoronaryinterventioninsightsfromtheptrgdesconsortium
AT younghoonjeongmdphd effectofcalciumchannelblockersonantiplateletactivityofclopidogrelinpatientsundergoingpercutaneouscoronaryinterventioninsightsfromtheptrgdesconsortium
AT byeongkeukkimmdphd effectofcalciumchannelblockersonantiplateletactivityofclopidogrelinpatientsundergoingpercutaneouscoronaryinterventioninsightsfromtheptrgdesconsortium
AT hyungjoonjoomdphd effectofcalciumchannelblockersonantiplateletactivityofclopidogrelinpatientsundergoingpercutaneouscoronaryinterventioninsightsfromtheptrgdesconsortium
AT kiyukchangmdphd effectofcalciumchannelblockersonantiplateletactivityofclopidogrelinpatientsundergoingpercutaneouscoronaryinterventioninsightsfromtheptrgdesconsortium
AT yongwhiparkmdphd effectofcalciumchannelblockersonantiplateletactivityofclopidogrelinpatientsundergoingpercutaneouscoronaryinterventioninsightsfromtheptrgdesconsortium
AT sunggyunahnmdphd effectofcalciumchannelblockersonantiplateletactivityofclopidogrelinpatientsundergoingpercutaneouscoronaryinterventioninsightsfromtheptrgdesconsortium
AT sangyeupleemdphd effectofcalciumchannelblockersonantiplateletactivityofclopidogrelinpatientsundergoingpercutaneouscoronaryinterventioninsightsfromtheptrgdesconsortium
AT jungraechomdphd effectofcalciumchannelblockersonantiplateletactivityofclopidogrelinpatientsundergoingpercutaneouscoronaryinterventioninsightsfromtheptrgdesconsortium
AT hyosookimmdphd effectofcalciumchannelblockersonantiplateletactivityofclopidogrelinpatientsundergoingpercutaneouscoronaryinterventioninsightsfromtheptrgdesconsortium
AT moohyunkimmdphd effectofcalciumchannelblockersonantiplateletactivityofclopidogrelinpatientsundergoingpercutaneouscoronaryinterventioninsightsfromtheptrgdesconsortium
AT dosunlimmdphd effectofcalciumchannelblockersonantiplateletactivityofclopidogrelinpatientsundergoingpercutaneouscoronaryinterventioninsightsfromtheptrgdesconsortium
AT eunseokshinmdphd effectofcalciumchannelblockersonantiplateletactivityofclopidogrelinpatientsundergoingpercutaneouscoronaryinterventioninsightsfromtheptrgdesconsortium
AT jungwonsuhmdphd effectofcalciumchannelblockersonantiplateletactivityofclopidogrelinpatientsundergoingpercutaneouscoronaryinterventioninsightsfromtheptrgdesconsortium
AT effectofcalciumchannelblockersonantiplateletactivityofclopidogrelinpatientsundergoingpercutaneouscoronaryinterventioninsightsfromtheptrgdesconsortium